Comprehensive Genomic Profiling (CGP) of whole blood “liquid biopsy” specimens from cancer patients is being performed in increasing numbers when tumor tissue is inaccessible or unavailable. Consequently, a thorough validation is critical in establishing clinical utility.
In this workshop, we will discuss important considerations when establishing a ctDNA CGP assay to ensure high sensitivity and concordance; share practical implementation challenges and proposed solutions experienced in a community-based, Integrated Network Cancer Program. We will also highlight the benefits of in-house CGP testing for both tissue and liquid.
William LaFramboise, PhD
Chief Genomics Technology Officer
Allegheny Health Network
Your email address is never shared with third parties.